# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
On June 18, 2024, Allarity Therapeutics, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Staff (t...
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved- On Track to Regain Compliance with All N...